| Literature DB >> 35539193 |
Linzhen Hu1,2, Yanfei Liu3, Yanxing Wang4, Zhenzhen Wang2, Jinfeng Huang2, Yongbo Xue2, Junjun Liu2, Zhenming Liu4, Yong Chen1, Yonghui Zhang2.
Abstract
Kaposi's sarcoma associated herpesvirus (KSHV) has gained considerable attention as a type of carcinogenic pathogen. Recent research suggests that KSHV has participated in the pathogenesis of Kaposi's sarcoma-related malignant neoplastic diseases. Viral lytic infection might be pivotal for the etiopathogenesis of KSHV-induced diseases; however, most clinical KSHV lytic replication inhibitors like ganciclovir, nelfinavir, or cidofovir do not restrain virus replication effectively enough to achieve clinical efficacy. In our continued pharmaceutical studies on Chinese herbal medicines, new acylphloroglucinol-based meroterpenoid enantiomers have been discovered from Hypericum japonicum. Most of these metabolites have potential inhibitory activities that target KSHV lytic replication. Amongst these analogues, compounds 1a and 1b possess an unreported ring system cyclopenta[b]chromene. Compounds 1a with 4a exhibit stronger inhibitory activities towards the lytic replication of KSHV in Vero cells. In addition, 1a and 4a have IC50 values of 8.30 and 4.90 μM and selectivity indexes of 23.49 and 25.70, respectively. Qualitative and quantitative SAR and molecular docking studies for acylphloroglucinol-based meroterpenoids with regard to anti-KSHV activity were conducted. An explanation for the variation in the activity and selectivity indexes was proposed in accordance with the predicted binding pose found with molecular docking to a putative target, thymidylate synthase (kTS). Compounds 1a and 4a have potential for further development and optimization of their anti-KSHV activities which could lead to new candidate drugs. This journal is © The Royal Society of Chemistry.Entities:
Year: 2018 PMID: 35539193 PMCID: PMC9081833 DOI: 10.1039/c8ra04073g
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Chemical structures of compounds 1a/1b–8a/8b.
1H NMR (400 MHz) and 13C (100 MHz) data for japonicols E–H (1–4) (δ in ppm, J in Hz)a
| No. | 1 | 2 | 3 | 4 | ||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
| 1 | 2.35 dd (14.1, 10.6), 2.68 dd (14.1, 10.6) | 22.3 | 2.85 dd (16.6, 5.8), 2.45 dd (16.6, 8.1) | 26.8 | 3.02 m | 27.7 | 3.04 m | 27.7 |
| 2 | 1.91 dd (10.8, 4.5) | 51.7 | 3.86 dd(8.1, 5.8) | 67.2 | 4.70 dd (9.2, 8.2) | 91.9 | 4.74 t (8.7) | 91.9 |
| 3 | 81.4 | 81.6 | 74.4 | 74.4 | ||||
| 4 | 1.76 m | 42.4 | 1.80 m, 1.72 m | 39.1 | 1.52 m | 39.5 | 1.54 m | 39.5 |
| 5 | 1.46 d (13.6), 1.82 m | 29.5 | 2.20 m, 2.16 m | 23.2 | 2.11 m | 23.1 | 2.13 m | 23.1 |
| 6 | 2.54 dd (19.7, 8.7) | 54.9 | 5.14 t (7.2) | 125.1 | 5.13 m | 125.7 | 5.14 t (7.1) | 125.7 |
| 7 | 148.7 | 132.8 | 132.6 | 132.6 | ||||
| 8 | 4.69 s | 111.2 | 1.62 s | 17.9 | 1.63 s | 17.8 | 1.64 s | 17.8 |
| 4.80 s | ||||||||
| 9 | 1.72 s | 18.9 | 1.69 s | 26.0 | 1.68 s | 26.0 | 1.69 s | 26.0 |
| 10 | 1.00 s | 28.7 | 1.27 s | 18.7 | 1.20 s | 22.0 | 1.23 s | 22.1 |
| 1′ | 163.5 | 157.2 | 168.2 | 168.5 | ||||
| 2′ | 108.0 | 101.5 | 105.6 | 106.7 | ||||
| 3′ | 164.1 | 164.3 | 161.4 | 159.2 | ||||
| 4′ | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
| 5′ | 162.2 | n.d. | 165.3 | 164.0 | ||||
| 6′ | 104.8 | n.d. | 105.5 | 105.8 | ||||
| 7′ | 212.1 | 211.0 | 212.1 | 201.0 | ||||
| 8′ | 4.02 sept (6.8) | 40.1 | 3.95 sept (6.7) | 40.1 | 3.98 sept (6.7) | 40.1 | ||
| 9′ | 1.12 d (6.8) | 19.9 | 1.13 d (6.7) | 19.9 | 1.12 d (6.7) | 19.9 | ||
| 10′ | 1.14 d (6.8) | 20.0 | 1.15 d (6.7) | 20.4 | 1.14 d (6.7) | 19.9 | ||
| 1′′ | 143.3 | |||||||
| 2′′ | 7.58 d (8.3) | 129.4 | ||||||
| 3′′ | 7.39 m | 128.8 | ||||||
| 4′′ | 7.46 m | 132.6 | ||||||
| 5′′ | 7.37 m | 128.8 | ||||||
| 6′′ | 7.56 d (8.3) | 129.4 | ||||||
Record in methanol-d4, n.d. means no detected.
Fig. 2Chromatograms showing the enantioseparation of racemates 1a/1b–4a/4b. HPLC chromatographic specifications were the following: mobile phase of hexane/isopropanol 94/6 (v/v) for 1a/1b, 99/1 (v/v) for 2a/2b, 93.5/6.5 (v/v) for 3a/3b, and 98/2 (v/v) for 4a/4b; flow rate of 3.0 mL min−1; column temperature of 25 °C; UV detection at 240 nm; semipreparative chromatographic column, CHIRALPAK®IC column (10 × 250 mm, 5 μm particles, Daicel, China). All mass ratios of 1a/1b–4a/4b were roughly 1 : 1.
Fig. 3Key 2D NMR correlations of compound 1.
Fig. 4Experimental ECD spectra of 1a/1b–4a/4b and calculated ECD spectra of 1b, 2a/2b, and 3b.
Fig. 5(A) Key 2D NMR correlations for the core structures of 3 and 4; (B) six preferential rotamers in Newman projections for C-2/C-3 of 3.
Antci-KSHV activities of compounds 1a/1b–8a/8b (μM)
| Compounds | CC50 | IC50 | Selective index (CC50/IC50) |
|---|---|---|---|
| Cidofovir | >1.00 | 0.0081 | >123.30 |
| 1a | 195.00 | 8.30 | 23.49 |
| 1b | 190.20 | 24.46 | 7.78 |
| 2a | 126.00 | 28.00 | 4.50 |
| 2b | 150.20 | 27.3 | 5.50 |
| 3a | 79.50 | 21.73 | 3.66 |
| 3b | 50.10 | 6.70 | 7.48 |
| 4a | 125.90 | 4.90 | 25.70 |
| 4b | >200.00 | 29.46 | >6.79 |
| 5a | >500.00 | 202.90 | >2.46 |
| 5b | >500.00 | 140.90 | >3.55 |
| 6a | 140.60 | 8.75 | 16.06 |
| 6b | 173.70 | 29.13 | 5.96 |
| 7a | 221.10 | 17.67 | 12.51 |
| 7b | >300.00 | 39.80 | >7.50 |
| 8a | >300.00 | 40.00 | >7.50 |
| 8b | >300.00 | 158.50 | >1.89 |
Positive control.
Fig. 6Ligands were aligned through flexible shape-based alignment, which was implemented in Schrödinger Suite.
Data set assignment, observed and predicted activity, and their residuals (prediction error) of training and test set
| Ligand name | QSAR set | Observed activity | Predicted activity | Prediction error |
|---|---|---|---|---|
| 4a | Training | 0.690 | 1.070 | −0.380 |
| 4b | Training | 1.469 | 1.289 | 0.180 |
| 3b | Training | 0.826 | 1.030 | −0.204 |
| 6a | Training | 1.247 | 1.228 | 0.019 |
| 3a | Training | 1.337 | 1.305 | 0.032 |
| 2b | Training | 1.436 | 1.302 | 0.135 |
| 2a | Training | 1.447 | 1.319 | 0.128 |
| 1b | Training | 1.388 | 1.384 | 0.005 |
| 8a | Training | 1.602 | 1.426 | 0.176 |
| 7a | Training | 0.942 | 1.355 | −0.413 |
| 6b | Training | 1.600 | 1.469 | 0.130 |
| 5b | Training | 2.149 | 1.963 | 0.186 |
| 8b | Training | 2.200 | 2.022 | 0.178 |
| 1a | Test | 0.919 | 1.305 | −0.385 |
| 7b | Test | 1.464 | 1.201 | 0.263 |
| 5a | Test | 2.307 | 1.477 | 0.831 |
PLS statistics of field-based QSAR modela
| Factors | SDtrain |
|
|
| RMSEtest |
| Pearson's |
|---|---|---|---|---|---|---|---|
| 1 | 0.2861 | 0.6184 | 17.8 | 0.00143 | 0.54 | 0.0944 | 0.771 |
| 2 | 0.1922 | 0.8434 | 26.9 | 9.42 × 10−5 | 0.55 | 0.072 | 0.7102 |
Factors = number of PLS factors in the model; R2 = correlation coefficient of experimentally observed and predicted activity; SD = standard deviation of regression; F = variance ratio; p = statistical significance; Q2 = value of Q2; RMSE = root mean square error; Pearson's r = correlation coefficient of predicted and experimentally observed activity.
Best model.
Fig. 7Scatter plots of observed versus predicted activities.
Docking results for 4a to kPr and kTS at SP level of precision
| Receptor | Glide GScore (kcal mol−1) |
|---|---|
| kPr ( | −6.035 |
| kTS ( | −8.033 |
Fig. 8Induced fit docking of 4a to kTS (5H39): (A) binding pose; (B) 2D interaction diagram.